$BMEA News
Last published 1d ago
- 1d agoBMEABiomea Fusion Reports Third Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireSAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the third quarter ended September 30, 2026, and provided a business update.
- 4w agoBMEABiomea Fusion BMF-650 (GLP-131) Phase I Topline Results Conference Call - BIOMEA FUSION INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Biomea Fusion BMF 650 GLP-131 Phase 1 Topline Results Conference Call. At this time, all participants are in a listen-only mode. Please be advised that today's conf
- 4w agoBMEABiomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor AgonistGlobeNewswireMean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo.No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related discontinuations
- 1mo agoBMEABiomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor AgonistGlobeNewswireSAN CARLOS, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company, today announced that it will report
- 2mo agoBMEABiomea Fusion to Participate in Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Company" or "Company management") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today
- 2mo agoBMEABiomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 DiabetesGlobeNewswireTopline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes ("T2D") patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first
- 3mo agoBMEABiomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in ObesityGlobeNewswire• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes SAN CARLOS, Calif.,
- 3mo agoBMEABiomea Fusion Reports Second Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireEnrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes ("T2D"); data expected in the first quarter of 2027Enrollment also ongoing for the Phase II
- 5mo agoBMEABiomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 StudyGlobeNewswire•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary
- 5mo agoBMEAJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - BIOMEA FUSION INCEarnings Call TranscriptsWelcome, everyone, to Jeffery's 2026 Global Healthcare Conference. My name is Roger Song, covering Semicat Biotech. It is my pleasure to have the five-side chat with our company, Biomia Fusion, and then we have COO, Rems
- 5mo agoBMEABiomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in ObesityGlobeNewswireCollaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic OutcomesLate-Breaking Preclinical Findings
- 6mo agoBMEABiomea Fusion to Participate at Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in
- 6mo agoBMEABiomea Fusion Reports First Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireSuccessfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to dateTopline data
- 6mo agoBMEABiomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific SessionsGlobeNewswireSAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that three
- 6mo agoBMEABiomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib TreatmentGlobeNewswireA 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence observed through Week
- 7mo agoBMEABiomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care TherapiesGlobeNewswireCOVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline 26-week primary endpoint
- 7mo agoBMEABiomea Fusion Reports Full Year 2025 Financial Results and Corporate HighlightsGlobeNewswireInitiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026Completed 52-week follow-up from Phase II trial
- 8mo agoBMEABiomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026GlobeNewswireSAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion," or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo
- 8mo agoBMEABiomea Fusion to Participate at Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Company" or "Company management") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it will
- 10mo agoBMEABiomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 MilestonesGlobeNewswireAdvancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes ("T2D") and in T2D patients currently failing glucagon-like peptide-1
- 10mo agoBMEABiomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive
- 11mo agoBMEABiomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025GlobeNewswireKey Opinion Leader, Dr. Ralph DeFronzo presents the "Future of Menin Inhibitors" and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE
- 11mo agoBMEABiomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)GlobeNewswireSAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it presented
- 11mo agoBMEABiomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)GlobeNewswireSAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it has been
- 11mo agoBMEABiomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025,
- 11mo agoBMEABiomea Fusion to Participate at Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it will
- 1y agoBMEABiomea Fusion to Participate at Jefferies London Healthcare ConferenceGlobeNewswireSAN CARLOS, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it is
- 1y agoBMEABiomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025GlobeNewswireThe Company's investigational small molecule glucagon-like peptide-1 ("GLP-1") receptor agonist ("RA"), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A Phase I study of
- 1y agoBMEABiomea Fusion Reports Third Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswireAdvances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea's next-generation, oral small molecule glucagon-like peptide-1 ("GLP-1") receptor agonist
- 1y agoBMEABiomea Fusion to Present Poster Presentations at ObesityWeek®2025GlobeNewswireSAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at
- 1y agoBMEABiomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor AgonistGlobeNewswireSAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the
- 1y agoBMEABiomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat SeriesGlobeNewswireSAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi's SMID Biotech C-Suite
- 1y agoBMEABiomea Fusion Announces Pricing of Public Offering of SecuritiesGlobeNewswireSAN CARLOS, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten
- 1y agoBMEABiomea Fusion Announces Proposed Public Offering of SecuritiesGlobeNewswireSAN CARLOS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering
- 1y agoBMEABiomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient PopulationsGlobeNewswireIcovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline,
- 1y agoBMEABiomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN CARLOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on September 24, 2025,
- 1y agoBMEABiomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate UpdateGlobeNewswireIn a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given semaglutide
- 1y agoBMEABiomea Fusion Reports Second Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswireThree presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib
- 1y agoBMEABiomea Fusion Appoints Julianne Averill to its Board of DirectorsGlobeNewswireSAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced the
- 1y agoBMEABiomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human PrimatesGlobeNewswireDose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the
- 1y agoBMEABiomea Fusion Announces Pricing of Public Offering of SecuritiesGlobeNewswireREDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten
- 1y agoBMEABiomea Fusion Announces Proposed Public Offering of SecuritiesGlobeNewswireREDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering
- 1y agoBMEABiomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025GlobeNewswireREDWOOD CITY, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary
- 1y agoAVAIBLCOBMEAEYEN+1Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue OpportunitiesGlobeNewswirePALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus
- 1y agoBMEABiomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute LeukemiaGlobeNewswireREDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the
- 1y agoBMEABiomea Fusion Reports First Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswireCompany Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients
- 1y agoBMEABiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025,
- 1y agoBMEABiomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate HighlightsGlobeNewswireMick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025
- 1y agoBMEABiomea Fusion Announces Leadership TransitionGlobeNewswireBoard member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion,
- 1y agoBMEAIcovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last DoseGlobeNewswireTherapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovamenib Strong